BioLife Solutions, Inc.

As of June 30, 2026, BioLife Solutions, Inc. carries a market capitalization of 1.20B, placing it among publicly traded companies globally. Its enterprise value stands at 1.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioLife Solutions, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, BioLife Solutions, Inc. has 48.89M shares outstanding.

As of June 30, 2026, BioLife Solutions, Inc. trades at a trailing price-to-earnings ratio of 23.44. The price-to-sales ratio is 13.22, and the price-to-book ratio stands at 3.27.

As of June 30, 2026, BioLife Solutions, Inc. trades at an EV/EBITDA multiple of 203.95 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 12.72 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 438.56 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.14B versus a market cap of 1.20B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioLife Solutions, Inc. maintains a current ratio of 9.69, meaning it holds 9.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, BioLife Solutions, Inc. posted a return on equity (ROE) of 15.12, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 13.89, measuring how efficiently the asset base is converted into earnings. The company generates approximately 576,901.25 in revenue per employee across its workforce of 156.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.17 indicates how many times BioLife Solutions, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, BioLife Solutions, Inc. recorded an income tax benefit of -37.10M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 7.06M, leaving 50.75M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 5, 2026, BioLife Solutions, Inc.'s stock has gained approximately 50.88% over the past 52 weeks. The 50-day moving average sits at 31.08, while the 200-day moving average is 23.09.

Over the twelve months ended June 30, 2026, BioLife Solutions, Inc. generated 90.00M in revenue and converted that into 50.75M in net income, yielding earnings per share of 0.90. EBITDA reached 5.61M, while operating income came in at 2.61M.

As of June 30, 2026, BioLife Solutions, Inc. holds 72.14M in cash and equivalents against 13.78M in total debt, resulting in a net debt position of -21.00M. Total book value stands at 367.63M, with working capital of 106.13M providing operational flexibility.

BioLife Solutions, Inc. produced 14.77M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -7.68M in capital expenditures, free cash flow totaled 7.10M - equivalent to 0.15 per share.

Over the twelve months ended June 30, 2026, BioLife Solutions, Inc. posted a gross margin of 63.88, reflecting its pricing power and cost economics. The operating margin of 2.90 and net profit margin of 56.39 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.59, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.20, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BioLife Solutions, Inc. shareholders.

BioLife Solutions, Inc.'s most recent stock split took place on January 29, 2014 with a 14:1 split ratio.

As of June 30, 2026, BioLife Solutions, Inc. has an Altman Z-Score of 29.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.